Sequential anticancer therapy in a patient with metachronous primary uterine cancer and breast cancer
https://doi.org/10.18027/2224-5057-2020-10-3
Abstract
Breast cancer (BC) is a heterogeneous disease characterized by the presence or absence of membrane receptor overexpression on tumor cells that correlates with the disease prognosis. Understanding of the patterns and mechanisms of tumor progression gained through clinical experience of managing BC patients is important. The treatment strategy depends on the hormone receptor status of the tumor, the HER2 / neu expression, and the proliferative activity level. A clinical case of advanced luminal A breast cancer is reported, and the rationale for sequential treatment strategy is provided taking into account the clinical situation and clinical course of the disease. Adequate endocrine therapy for hormone-positive metastatic BC provides long-term tumor control like in this case, as well as a high quality of life over the entire course of sequential treatment with anticancer drugs.
About the Authors
A. V. Sultanbaev
Republican Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Alexander V. Sultanbaev, MD, PhD, Head of the Department of Anticancer Drug Therapy
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
A. F. Nasretdinov
Republican Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Ainur F. Nasretdinov, Oncologist, Outpatient Department of Anticancer Drug Therapy
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
N. I. Sultanbaeva
Republican Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Nadezhda I. Sultanbaeva, Oncologist, 1st Department of Anticancer Drug Therapy
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
K. V. Menshikov
Republican Clinical Oncological Dispensary;
Bashkir state medical university
Russian Federation
Competing Interests:
Russian Federation
Konstantin V. Menshikov, MD, PhD, Associate Professor, Department of Oncology with Oncology and Pathology Courses; Oncologist, Department of Chemotherapy
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
Sh. I. Musin
Republican Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Shamil I. Musin, MD, PhD, Head of the 6th Department of Surgery
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
A. A. Izmailov
Republican Clinical Oncological Dispensary;
Bashkir state medical university
Russian Federation
Competing Interests:
Russian Federation
Adel A. Ismailov, MD, PhD, DSC, Chief Physician
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
O. N. Lipatov
Bashkir state medical university
Russian Federation
Competing Interests:
Russian Federation
Oleg N. Lipatov, MD, PhD, DSC, Professor, Department of Oncology with Oncology and Pathology Courses
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
V. A. Pushkarev
Republican Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Vasily A. Pushkarev, MD, PhD, DSC, Oncologist, 8th Department of Surgery
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
R. B. Valiakhmedov
Republican Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Rustam B. Valiachmedov, Oncologist, Department of Anticancer Drug Therapy
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
A. V. Pushkarev
Republican Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Alexey V. Pushkarev, Oncologist, 5th Department of Surgery
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
F. F. Mufazalov
Republican Clinical Oncological Dispensary;
Bashkir state medical university
Russian Federation
Competing Interests:
Russian Federation
Fagim F. Mufazalov, MD, PhD, DSC, Professor; Head of the Radiation Oncology Department
Ufa
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов по представленной статье.
References
1. Насретдинов А. Ф., Султанбаева Н. И., Мусин Ш. И. и др. Терапия ингибиторами циклинзависимых киназ CDK4/6 при разных спектрах соматических мутаций гена PIK3CA у больных раком молочной железы. Медицинский совет. 2020; (20):40-46. doi: 10.21 518/2079-701X-2020-20-40-46.
2. Sultanbaev, A. & Minniakhmetov, I. & Sultanbaeva, N. & Menshikov, K. & Nasretdinov, A. & Musin, S.. (2020). 25P Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia. Annals of Oncology. 31. S1250. https://doi.org/10.1016/j. annonc. 2020.10.045.
3. Состояние онкологической помощи населению России в 2019 году. Под. ред. А. Д. Каприна, В. В. Старинского, А. О. Шахазадовой. М.: МНИОИ им. П. А. Герцена. 2020; 239 с. [Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossiiv 2019 godu. (The status of cancer care for the population of Russia in 2019.) A. D. Kaprin, V. V. Starinskiy, A. O. Shahazadova eds. М.: MNIIOI named by P. A. Herzen. 2020; 239 р. (In Russ.)]
4. Насретдинов А. Ф., Султанбаева Н. И., Мусин Ш. И. и др. Уровень опухоль-инфильтрирующих лимфоцитов и PD-статус как возможные прогностические маркеры выживаемости и эффективности терапии при трижды негативном раке молочной железы. Опухоли женской репродуктивной системы. 2020. Т. 16. № 1. С. 65-70. https:// doi.org/10.17 650/1994-4098-2020-16-1-65-70.
5. Wangchinda P., Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Onc. 2016;14:223. doi: 10.1186/s12 957-016-0988-0. 7.
6. Ye J., Wang W., Xin L. et al. The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China. Anticancer Res. 2017;37 (8):4549-4556. doi: 10.21 873/anticanres. 11 852.
7. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66 (1):7-30. doi: 10.3322/caac. 21 332.
8. Rossi V., Berchialla P., Giannarelli D. et al. Should All Patients With HR-Positive HER2‑Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers (Basel). 2019;11 (11):1661. doi: 10.3390/cancers11 111 661.
9. Султанбаев А. В., Насретдинов А. В., Мусин Ш. И. и др. Эффективность гормонотерапии больных раком молочной железы при наличии мутации в гене PIK3СА. Евразийский онкологический журнал. 2020. Т. 8, № 2. Приложение. С21.
10. Thill, M., & Schmidt, M. (2018). Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitorbased treatment in breast cancer. Therapeutic advances in medical oncology, 10, 1 758 835 918 793 326. https://doi.org/10.1177/1 758 835 918 793 326
11. García-Trevijano Cabetas, M., Lucena Martínez, P., Jiménez Nácher, I. et al. (2020). Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer. International journal of clinical pharmacy, 10.1007/s11 096-020-01 193‑z. Advance online publication. https://doi.org/10.1007/s11 096-020-01 193‑z
12. Pandey, K., An, H. J., Kim, S. K. et al. (2019). Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. International journal of cancer, 145 (5), 1179-1188. https://doi.org/10.1002/ijc. 32 020
13. Kim, S., Tiedt, R., Loo, A., Horn, T., Delach, S., Kovats, S., Haas, K., Engstler, B. S., Cao, A., Pinzon-Ortiz, M., Mulford, I., Acker, M. G., Chopra, R., Brain, C., di Tomaso, E., Sellers, W. R., & Caponigro, G. (2018). The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. Oncotarget, 9 (81), 35 226-35 240. https://doi.org/10.18 632/oncotarget. 26 215
14. Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, Yu X, Nagata A, VanArsdale T, Murray BW. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol Cancer Ther. 2016 Oct;15 (10):2273-2281. doi: 10.1158/1535-7163. MCT-16-0300. Epub 2016 Aug 5. PMID: 27 496 135
15. Wander SA, Zangardi M, Niemierko A, et al: A multicenter analysis of abemaciclib after progression on palbociclib in patients with hormone receptor-positive/HER2 - metastatic breast cancer. 2019 ASCO Annual Meeting. Abstract 1057. Presented June 2, 2019 DOI: 10.1200/JCO. 2019.37.15_suppl. 1057
16. Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., Burris, H. A., 3rd, Provencher, L., Neven, P., Gnant, M., Shtivelband, M., Wu, C., Fan, J., Feng, W., Taran, T., & Baselga, J. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2‑negative advanced breast cancer: overall survival results from BOLERO-2†. Annals of oncology: official journal of the European Society for Medical Oncology, 25 (12), 2357-2362. https://doi.org/10.1093/annonc/mdu456
17. Cook M, Al Rabadi L, Mitri ZI, et al: Everolimus and exemestane for the treatment of metastatic hormone receptorpositive breast cancer patients previously treated with CDK4/6 inhibitor-based therapies... 2019 ASCO Annual Meeting. Abstract 1058. Presented June 2, 2019 DOI: 10.1200/JCO. 2019.37.15_suppl. 1058
Review
For citations:
Sultanbaev A.V., Nasretdinov A.F., Sultanbaeva N.I., Menshikov K.V., Musin Sh.I., Izmailov A.A., Lipatov O.N., Pushkarev V.A., Valiakhmedov R.B., Pushkarev A.V., Mufazalov F. . Sequential anticancer therapy in a patient with metachronous primary uterine cancer and breast cancer. Malignant tumours. 2020;10(4):38-46. (In Russ.) https://doi.org/10.18027/2224-5057-2020-10-3
Views:
535
Email this article 